Colitis Home > Infliximab
In clinical studies, infliximab has been shown to improve the symptoms of plaque psoriasis. In one study, up to 88 percent of those taking it showed a large improvement in their psoriasis symptoms, compared to just 6 percent of those not taking the drug.
In a study of infliximab for psoriatic arthritis, the drug was shown to reduce pain and other symptoms, including joint stiffness. Also, the medication helped to lessen the physical joint changes of psoriatic arthritis, compared to those not taking it.
In clinical studies looking at infliximab as a rheumatoid arthritis treatment, the drug was shown to improve the symptoms of rheumatoid arthritis. In these studies, people took either methotrexate (Rheumatrex®) plus infliximab or methotrexate alone. More of the people taking the combination of drugs showed improvement, compared to the people taking just methotrexate. In these studies, people usually noticed improvement within the first two weeks of taking infliximab. The medication also improved the physical joint changes that can occur in rheumatoid arthritis.
In studies of infliximab for ulcerative colitis treatment, the drug was shown to improve the symptoms of ulcerative colitis and promote healing of the lining of the gastrointestinal tract. People taking the drug were also more likely to experience remission of ulcerative colitis, compared to those not taking it.